Prevalence of scars: an international epidemiological survey in adults

Dear Editor,

Skin is the most vulnerable organ that is constantly exposed to potential injury, and wound healing is a vital process for the survival of all higher organisms.¹ Scarring is most noticeable in the skin, but it also affects almost all adult mammalian and human tissues and organs.² They may result from surgery, skin injury, burning or inflammatory skin diseases, such as acne, chickenpox or shingles.³ Scars may be extensive, dystrophic, appearing on areas not covered by clothes and considered embarrassing. They may also be associated with symptoms such as pruritus, pain or other discomforts. According to a study conducted in the United Kingdom, 26% and 44% of patients reported pain and itching related to their scars, impacting their physical comfort and

functioning.⁴ Usually, scars are composed of loose fibrous connective tissue and are remodelled during healing.⁵ Chronic inflammation of the dermis and uncontrolled activation of myofibroblasts may result in abnormal scar overgrowth leading to a hypertrophic scar or a keloid with an excess of extracellular matrix proteins.⁶ Despite being common throughout the world, the epidemiology of scars has not yet been properly investigated.

The aim of this international epidemiological study was to assess the prevalence of scars worldwide. The present article describes the general population with participants reporting at least one scar having appeared during the year prior to this study.

Our participants were selected *via* a stratified random sampling method of internet users who agreed to participate in panel surveys. Data about sociodemography, presence, origin and symptoms of scars using an internet survey were collected between April and May 2020. The survey focused on the most recent scars reported in order to simplify data collection.

Table 1	Sociodemographic	data and general	data about scars
---------	------------------	------------------	------------------

	Global N = 11 100 43.0 ± 14.9		Men		Women		
			N = 5486 42.8 ± 14.9		N = 5614		
					43.2 ± 14.9		
Age							
mean \pm SD	n	%	n	%	n	%	
Age range (years)							
18–24	1367	12.32	694	12.65	673	13.67	
25–34	2430	21.89	1214	22.13	1216	24.30	
35–44	2289	20.62	1126	20.52	1163	22.89	
45–54	2093	18.86	1036	18.88	1057	20.93	
55–64	1781	16.05	893	16.27	888	17.81	
>65	1140	10.27	523	9.53	617	11.40	
Mean number of scars \pm SD	4.1 ± 4.9			4.0 ± 4.5		$\textbf{4.2}\pm\textbf{5.0}$	
Number of scars							
< one year	1196	22.2	602	22.7	594	21.7	
> one year	4186	77.8	2046	77.3	2140	78.3	
Time since presence, if > one year (years)	12.4 ± 12.7		12.5 ± 13.0		12.3 ± 12.4		
Origin of scars							
Accident	2992	55.59	1604	60.57	1388	50.77	
General/orthopaedic surgery	1712	31.81	741	27.98	971	35.52	
Skin excision	299	5.56	132	4.98	167	6.11	
Restorative/cosmetic surgery	251	4.66	125	4.72	126	4.61	
Cosmetic procedure	128	2.38	46	1.74	82	3.00	
Type of scars							
Hyperthropic or keloid scar	671	12.47	335	12.65	336	12.29	
Did not know	1897	35.25	1897	35.25	949	34.71	

SD, standard deviation.

© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd

on behalf of European Academy of Dermatology and Venereology.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Table 2 Prevalence of clinical symptoms

Globa	Global		Men			Women		
n	%	Intensity>5 (0-10)	n	%	Intensity>5 (0-10)	n	%	Intensity>5 (0–10)
1774	32.96%	10.80%	963	36.37%	12.61%	1198	43.82%	10.80%
2067	38.41%	15.09%	1094	41.31%	17.03%	736	26.92%	15.09%
2712	50.39%	20.09%	1389	52.45%	21.30%	1192	43.60%	20.09%
2519	46.80%	19.18%	1279	48.30%	20.43%	1240	45.35%	19.18%
2446	45.45%	17.58%	1254	47.36%	18.73%	1323	48.39%	17.58%
1631	3030%	10.18%	895	33.80%	12.01%	973	35.59%	10.18%
2453	45.58%	18.80%	1255	47.39%	19.86%	811	26.66%	18.80%
	Globa n 1774 2067 2712 2519 2446 1631 2453	Global n % 1774 32.96% 2067 38.41% 2712 50.39% 2519 46.80% 2446 45.45% 1631 3030% 2455 45.58%	Global n % Intensity>5 (0-10) 1774 32.96% 10.80% 2067 38.41% 15.09% 2712 50.39% 20.09% 2519 46.80% 19.18% 2446 45.45% 17.58% 1631 3030% 10.18% 24558 45.58% 18.80%	Global Men n % Intensity>5 (0-10) n 1774 32.96% 10.80% 963 2067 38.41% 15.09% 1044 2712 50.39% 20.09% 1389 2519 46.80% 19.18% 1279 2446 45.45% 17.58% 1254 1631 3030% 10.18% 895 2455 45.58% 18.80% 1255	Global Men n % Intensity>5 (0-10) n % 1774 32.96% 10.80% 963 36.37% 2067 38.41% 15.09% 1094 41.31% 2712 50.39% 20.09% 1389 52.45% 2519 46.80% 19.18% 1279 48.30% 2446 45.45% 17.58% 1254 47.36% 1631 3030% 10.18% 895 33.80% 2455 45.58% 18.80% 1254 47.36%	Global Men n % Intensity>5 (0-10) n % Intensity>5 (0-10) 1774 32.96% 10.80% 963 36.37% 12.61% 2067 38.41% 15.09% 1094 41.31% 17.03% 2712 50.39% 20.09% 1389 52.45% 21.30% 2519 46.80% 19.18% 1279 48.30% 20.43% 2446 45.45% 17.58% 1254 47.36% 18.73% 1631 3030% 10.18% 895 33.80% 12.01% 2453 45.58% 18.80% 1255 47.39% 19.86%	Global Men Men<	$ \begin{array}{ c c c c c } \hline \mbox{A} \$

Overall, 11 100 individuals from Brazil (2000), China (3050), France (2000), Russia (2000) and the United States (2050) answered the survey; 48.5% of subjects reported at least one scar, and in 22%, the most recent scar was less than one-yearold. The most often reported location of recent scars in women was the abdomen (20.4%) and face (15.9%); in men, it was the face (18.7%) and abdomen (13.2%). Significantly more men (13.3%, P < 0.00001) than women (8.4%) reported scars on their hands. For 50.8%, the origin of the most recent scar was accidental or due to a disease (women: 50.8%, men: 60.5%, P < 0.0001); 35% of women and 28% of men indicated that general or orthopaedic surgery caused the scarring (P < 0.0001). Details are given in Table 1. Overall, 12.3% of men and 10.7% of women who reported scars also reported pain (P < 0.03). Table 2 provides details about symptoms. In 2014, international guidelines on the management of scars were issued. However, these guidelines have not yet been updated.^{7,8} Currently, some procedures are available to manage scars, such as intralesional injections of corticosteroids and/or 5-fluorouracil, cryotherapy, radiotherapy, laser therapy and surgical interventions, together with additional measures such as sun protection, silicone-based dressings or gels.9,10 Scar management mainly consisted in the use of topical products such as healing creams (13.2%), antiseptic solutions (11.2%) or a topical antibiotic (11.9%). Medical care was significantly (P < 0.001) more frequently provided to subjects with painful scars.

To our knowledge, this is the first international epidemiological survey on the prevalence, origin, location and impact of scars. Further investigations need to be performed.

Acknowledgements

The authors acknowledge the technical support of G. Le Dantec and the writing support of Karl Patrick Goritz, SMWS—Scientific and Medical Writing Services, France.

Funding sources

This project was funded by La Roche Posay.

Conflict of interest

S. Seité, AL Demessant-Flavigny and C. LeFloc'h are employees of La Roche-Posay.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

J.M. Amici,¹ C. Taïeb,^{2,*} D C. LeFloc'h,³ A.-L. Demessant-Flavigny,³ S. Seité,³ O. Cogrel^{1,4} D ¹Dermatology Department, CHU Bordeaux, Hôpital Saint-André, Bordeaux, France, ²Patients Priority, European Market Maintenance Assessment, Fontenay-sous-Bois, France, ³La Roche-Posay, Levallois-Perret, France, ⁴Groupe Chirurgical de Dermatologie, French Society of Dermatological Surgery, Paris, France *Correspondence: Charles Taïeb. E-mail: charles.taieb@emma.clinic

References

- 1 Takeo M, Lee W, Ito M. Wound healing and skin regeneration. *Cold Spring Harbor perspectives in medicine* 2015; **5**: a023267-a.
- 2 Padmanabhan J, Maan ZN, Kwon SH, Kosaraju R, Bonham CA, Gurtner GC. In vivo models for the study of fibrosis. *Adv Wound Care (New Rochelle)* 2019; 8: 645–654.
- 3 Téot L, Mustoe TA, Middelkoop E, Gauglitz GG. Textbook on scar management: state of the art management and emerging technologies. Luc Téot Editors, Montpellier, France, 2020.
- 4 Brown BC, McKenna SP, Siddhi K, McGrouther DA, Bayat A. The hidden cost of skin scars: quality of life after skin scarring. *J Plast Reconstr Aesthet Surg* 2008; **61**: 1049–1058.
- 5 Reinke JM, Sorg H. Wound repair and regeneration. *Eur Surg Res* 2012; 49: 35–43.
- 6 Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. *Nature* 2008; **453**: 314–321.
- 7 Gold MH, Berman B, Clementoni MT, Gauglitz GG, Nahai F, Murcia C. Updated international clinical recommendations on scar management: part 1–evaluating the evidence. *Dermatol Surg* 2014; 40: 817– 824.
- 8 Gold MH, McGuire M, Mustoe TA *et al.* Updated international clinical recommendations on scar management: part 2–algorithms for scar prevention and treatment. *Dermatol Surg* 2014; **40**: 825–831.
- 9 Meaume S, Le Pillouer-Prost A, Richert B, Roseeuw D, Vadoud J. Management of scars: updated practical guidelines and use of silicones. *Eur J Dermatol* 2014; 24: 435–443.
- 10 Del Toro D, Dedhia R, Tollefson TT. Advances in scar management: prevention and management of hypertrophic scars and keloids. *Curr Opin Otolaryngol Head Neck Surg* 2016; 24: 322–329.

DOI: 10.1111/jdv.18277